Accutar Biotechnology Inc. has identified sulfonamides acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer.
There is still a percentage of patients with multiple myeloma (MM) who do not respond to initial therapy, and they are considered as refractory MM patients. There is a need for novel biomarkers of treatment response in refractory MM.
Treatment with injections of gonadotropin-releasing hormone (GnRH), indicated to prevent sexual maturation deficits in Down syndrome, also reduced cognitive function impairment associated with Down syndrome, also called trisomy 21. With age, about three-quarters of people with Down syndrome develop Alzheimer's disease. They also lose their sense of smell. Both circumstances could improve with pulse doses of GnRH, according to a study led by the French National Institute of Health and Medical Research (Inserm) and the University of Lausanne (UNIL) published in the Sept. 1, 2022, issue of Science.
Researchers from Pfizer Inc. presented preclinical data for the melanocortin MC4 receptor (MC4R) antagonist PF-07258669, being developed for the treatment of anorexia nervosa.
Circadian rhythm disorders are associated with psychiatric disorders including depression, bipolar disease and schizophrenia. To target casein kinase I isoform delta (CKI-delta), Janssen Pharmaceutica NV scientists sought potent, selective, brain-penetrant CKI-delta inhibitors which can be dosed daily and orally.
Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform.
MC2 Therapeutics A/S has discovered that carbamylation of proteins, peptides and amino acids in the skin, caused by isocyanate, may be the root cause of several urea-associated skin diseases, such as chronic kidney disease-associated pruritus (CKD-aP, or uremic pruritus) and genital lichen sclerosus.
Mas-related G-protein coupled receptor X2 (MRGPRX2) is expressed particularly on mast cells and its activation leads to the mast cell degranulation with release of inflammatory mediators.
RSS
